Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany.
Hepatol Commun. 2022 Apr;6(4):809-820. doi: 10.1002/hep4.1813. Epub 2021 Sep 1.
The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial. To identify predictors of jaundice resolution after ERCP and whether resolution is associated with improved patient outcomes, we conducted a retrospective cohort study of 124 patients with jaundice and PSC. These patients underwent endoscopic biliary balloon dilation and/or stent placement at an American tertiary center, with validation in a separate cohort of 102 patients from European centers. Jaundice resolved after ERCP in 52% of patients. Median follow-up was 4.8 years. Independent predictors of jaundice resolution included older age (P = 0.048; odds ratio [OR], 1.03 for every 1-year increase), shorter duration of jaundice (P = 0.059; OR, 0.59 for every 1-year increase), lower Mayo Risk Score (MRS) (P = 0.025; OR, 0.58 for every 1-point increase), and extrahepatic location of the most advanced biliary stricture (P = 0.011; OR, 3.13). A logistic regression model predicted jaundice resolution with area under the receiver operator characteristic curve of 0.67 (95% confidence interval, 0.5-0.79) in the validation set. Independent predictors of death or transplant during follow-up included higher MRS at the time of ERCP (P < 0.0001; hazard ratio [HR], 2.33 for every 1-point increase), lower total serum bilirubin before ERCP (P = 0.031; HR, 0.91 for every 1 mg/dL increase), and persistence of jaundice after endoscopic therapy (P = 0.003; HR, 2.30). Conclusion: Resolution of jaundice after endoscopic treatment of biliary strictures is associated with longer transplant-free survival of patients with PSC. The likelihood of resolution is affected by demographic, hepatic, and biliary variables and can be predicted using noninvasive data. These findings may refine the use of ERCP in patients with jaundice with PSC.
内镜逆行胰胆管造影术(ERCP)治疗原发性硬化性胆管炎(PSC)的益处仍存在争议。为了确定 ERCP 后黄疸消退的预测因素,以及是否与患者预后改善相关,我们对 124 例黄疸合并 PSC 患者进行了回顾性队列研究。这些患者在美国一家三级中心接受了内镜胆道球囊扩张和/或支架置入,在来自欧洲中心的 102 例患者的另一队列中进行了验证。52%的患者 ERCP 后黄疸消退。中位随访时间为 4.8 年。黄疸消退的独立预测因素包括年龄较大(P=0.048;每增加 1 岁,优势比 [OR] 为 1.03)、黄疸持续时间较短(P=0.059;OR,每增加 1 年,为 0.59)、较低的 Mayo 风险评分(MRS)(P=0.025;OR,每增加 1 分,为 0.58)和最严重胆道狭窄的肝外位置(P=0.011;OR,每增加 1 分,为 3.13)。验证组中,逻辑回归模型预测黄疸消退的受试者工作特征曲线下面积为 0.67(95%置信区间,0.5-0.79)。随访期间死亡或移植的独立预测因素包括 ERCP 时更高的 MRS(P<0.0001;HR,每增加 1 分,为 2.33)、ERCP 前总血清胆红素较低(P=0.031;HR,每增加 1mg/dL,为 0.91)和内镜治疗后黄疸持续存在(P=0.003;HR,每增加 1 分,为 2.30)。结论:胆道狭窄内镜治疗后黄疸消退与 PSC 患者无移植生存时间延长相关。消退的可能性受人口统计学、肝脏和胆道变量的影响,可使用非侵入性数据进行预测。这些发现可能会改进 ERCP 在伴有黄疸的 PSC 患者中的应用。